Antigen variant of Varicella Zoster virus and use thereof
AssigneeMogam Institute for Biomedical Research
InventorsHyo Jung Nam, Ga Young Ji, Eunmi Kim
Life of this patent
Estimating the term…
Abstract
An antigen variant and a use thereof are disclosed. The antigen variant is a protein, among surface proteins (gE) of the varicella zoster virus, exhibits a high expression level and high immunogenicity, and thus, when the antigen variant is used as a vaccine composition, the vaccine composition has more excellent safety compared to a live virus vaccine, and the antigen variant exhibits a higher expression level in a host cell compared to other antigens. The antigen variant is useful as a vaccine for preventing or treating chicken pox or herpes zoster caused by the varicella zoster virus.
Claims12
A vaccine composition comprising:
- (a) a variant of Varicella Zoster Virus (VZV) surface protein (gE) antigen, said VZV gE antigen comprising the base amino acid sequence of SEQ ID NO:
- 1 with the following mutations:
- 1) a carboxy terminal truncation starting at any one of the amino acid residues of positions 534, 535, 536, 537, 538, or 540,
- 2) wherein the amino acid residue at position 40 is threonine, and
- 3) wherein the amino acid residue at position 536, if present, is leucine;
- and
- (b) an adjuvant.
A recombinant vector comprising an exogenous gene encoding a variant of Varicella Zoster Virus (VZV) surface protein (gE) antigen,
- wherein the VZV gE antigen comprises the base amino acid sequence of SEQ ID NO:
- 1 with the following mutations;
- 1) A carboxy terminal truncation starting at any one of the amino acid residues of positions 534, 535, 536, 537, 538, or 540,
- 2) wherein the amino acid residue at position 40 is threonine;
- and
- 3) wherein the amino acid residue at position 536, if present, is leucine;
- and
- wherein the exogenous gene being operably linked to a promoter.
Dependencies are inferred from the claim text.